Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Reports Outline Medicinal Chemistry Study Results from Sanofi (Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:30pm CEST

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Medicinal Chemistry have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs."

The news reporters obtained a quote from the research from Sanofi, "Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery. Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients."

According to the news reporters, the research concluded: "Advances in cancer biology and drug discovery highlight this potential."

For more information on this research see: Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. Cell Chemical Biology, 2017;24(9):1058-1065. Cell Chemical Biology can be contacted at: Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA (see also Medicinal Chemistry).

Our news correspondents report that additional information may be obtained by contacting A.T. Plowright, Sanofi Aventis Deutschland GmbH, Integrated Drug Discovery, D-65926 Frankfurt, Germany. Additional authors for this research include C. Ottmann, M. Arkin, Y.P. Auberson, H. Timmerman and H. Waldmann.

Keywords for this news article include: Frankfurt, Germany, Europe, Medicinal Chemistry, Chemical Biology, Chemicals, Sanofi.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/23WiseTech Global acquires three leading logistics solution providers across La..
AQ
04/23WISETECH GLOBAL (ASX : WTC) Acquires Three Leading Logistics Solution Providers ..
AQ
04/21SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
AQ
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/20SANOFI : Advent International enters into exclusive negotiations to acquire Zent..
AQ
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
AQ
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
AQ
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
AQ
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
AQ
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
DJ
More news
News from SeekingAlpha
04/23MANNKIND : Experts In Pulling Numbers From Orifices 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 633 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,71%
P/E ratio 2018 16,06
P/E ratio 2019 14,21
EV / Sales 2018 2,76x
EV / Sales 2019 2,59x
Capitalization 82 385 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 746
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571